Hepatitis C Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

The hepatitis C market covers antiviral drugs, diagnostic tests, and care services aimed at managing and curing HCV infection, a blood-borne virus that can cause chronic liver disease, cirrhosis, and liver cancer. Direct-acting antivirals have transformed the treatment landscape by offering cure rates above 95% with shorter, oral regimens. Public health initiatives such as the World Health Organization's goal to eliminate viral hepatitis as a public health threat by 2030 are encouraging wider testing and treatment uptake.

• •Estimated 2025 market size is $48.55 billion with a compound annual growth rate of about 9.15%.
• •Treatment has shifted from interferon-based regimens to oral direct-acting antivirals.
• •WHO targets a 90% reduction in new chronic HCV infections and a 65% reduction in mortality by 2030.

Rising diagnosis rates, expanded access to pan-genotypic DAAs, and growing awareness of HCV's long-term complications are the primary drivers of market expansion. Increased government reimbursement and inclusion of hepatitis C drugs in national formularies are accelerating patient access, particularly in regions with historically low treatment penetration. Patent expiries of leading DAAs are also opening the door to generic competition, which can both expand volumes and pressure prices.

• •WHO estimates about 50 million people are living with chronic HCV globally, with most cases undiagnosed.
• •Pan-genotypic regimens such as sofosbuvir/velpatasvir simplify treatment and support scale-up.
• •Generic licensing through the Medicines Patent Pool has widened access in more than 100 low- and middle-income countries.

The market is typically segmented by drug class (NS3/4A protease inhibitors, NS5A inhibitors, NS5B polymerase inhibitors and combinations), treatment type (monotherapy versus combination therapy), and end user (hospitals, clinics, specialty centers). Regionally, North America and Europe have historically led in revenue due to early DAA adoption and high per-patient pricing, while Asia-Pacific, the Middle East and Africa are expected to be the fastest-growing regions as screening and treatment access expand.

• •DAAs account for the majority of revenue, with combination therapies growing fastest.
• •Asia-Pacific is projected to see the highest growth rate as countries like China and India scale national elimination programs.
• •High-burden regions include Eastern Europe, Central Asia, and parts of Africa and the Middle East.

What are the recent trends and outlook?

Looking ahead, the market is expected to benefit from simplified test-and-treat strategies, decentralized care models, and potential single-shot curative regimens. Pricing pressure from generics and volume growth from elimination programs are likely to reshape revenue patterns, rewarding companies that can combine innovative regimens with broad geographic reach. Over the longer term, an effective prophylactic HCV vaccine remains a key unmet need that could materially alter the market.

• •Point-of-care HCV RNA testing is enabling same-day diagnosis and treatment initiation.
• •Generic DAA production is reducing per-course costs from tens of thousands of dollars to under $100 in many low-income countries.
• •Several candidates are in clinical development targeting difficult-to-treat genotypes and resistance-associated substitutions.